Basit öğe kaydını göster

dc.contributor.authorAtasever, M
dc.contributor.authorErturan, Zayre
dc.contributor.authorAtalay, F
dc.contributor.authorUzun, M
dc.contributor.authorAkar, N
dc.contributor.authorKarahan, ZC
dc.date.accessioned2021-03-04T18:03:20Z
dc.date.available2021-03-04T18:03:20Z
dc.date.issued2004
dc.identifier.citationKarahan Z., Atalay F., Uzun M., Erturan Z., Atasever M., Akar N., "Sequence analysis of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Turkey", MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, cilt.10, ss.325-333, 2004
dc.identifier.issn1076-6294
dc.identifier.otherav_88b1e91b-8d29-4ae1-bd3b-47721f2aebee
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/92732
dc.identifier.urihttps://doi.org/10.1089/mdr.2004.10.325
dc.description.abstractDrug-resistant tuberculosis is a serious problem throughout the world. Resistance to Rifampicin (RIF) is mainly caused by the mutations in the rpoB gene coding the beta-subunit of RNA polymerase. In this study, we aimed to detect the distribution of rpoB gene mutations in 80 RIF-resistant clinical Mycobacterium tuberculosis (MTB) isolates from Turkey. The rpoB gene was amplified by PCR and mutations leading to RIF resistance were determined by automated sequence analysis. A total of 72 of the 80 isolates (90%) were found to carry mutations in the amplified region, whereas eight isolates (10%) carried no mutations. Overall, 24 different missense mutations affecting 14 codons, and two deletion mutants were identified. Nine new mutations, six in the hot-spot region and three outside this region, were found. The codon numbers of the most frequently encountered mutations were 531 (51.4%), 526 (18.1%), 516 (13.9%), and 513 (12.5%). As a result, 90% of the RIF-resistant MTB isolates from the Turkish patients were found to carry a mutation in the rpoB gene, Ser531Leu being the most frequent one. Although molecular methods identify mutations leading to RIF resistance very quickly, results of the antimycobacterial susceptibility tests must be taken into consideration for the patients carrying no mutations in this region.
dc.language.isoeng
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectEczacılık
dc.subjectSağlık Bilimleri
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectMikrobiyoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectİmmünoloji
dc.subjectBULAŞICI HASTALIKLAR
dc.titleSequence analysis of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Turkey
dc.typeMakale
dc.relation.journalMICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE
dc.contributor.department, ,
dc.identifier.volume10
dc.identifier.issue4
dc.identifier.startpage325
dc.identifier.endpage333
dc.contributor.firstauthorID173452


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster